Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IPIC -- Ignore unavailable to you. Want to Upgrade?

To: cardiologist to be who wrote (1082)	3/6/1998 1:09:00 PM
From: WeirdPro Randy	Respond to of 1359

<<my point was that the incidence of valvular disease with phen/fen is likely higher than reported and the scare is prompting a lot of unnecessary testing>> The incidence of valvular disease as reported from the inital FDA survey is > 30%, and you think it's likely to be higher? You are the someone with access to some numbers on echo's done on phen-fen and Redux patients, what are you seeing to make this statement. The precedent is that drug companies are not held responsible for the testing for potential side effects, you have only alluded to the significant numbers of people having echo's, not to the findings of such echo's. If the studies exonerate Redux, the lawyers are going to waste a hell of a lot of money if they wish to pursue a baseless case......something they will not wish to do if they aren't going to recoup these costs.